RJ Hamster
3 Stocks Surge Early 2026: Biotech Energy and Rare…
Ask An Advisor: I’m 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (From Finance Advisors)
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
Written by Nathan Reiff on February 2, 2026
In Brief
- Corvus Pharmaceuticals has nearly tripled in value this year amid optimism that its atopic dermatitis drug candidate will continue to deliver strong trial results.
- Despite legal and other hurdles, New Era Energy & Digital recently noted a key achievement in its path toward providing data center capacity.
- USA Rare Earth has received around $1.6 billion in federal funding as it seeks to provide a domestic alternative to foreign rare earth minerals.
Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall after multiple dips throughout January. However, that middling performance might obscure the fact that a number of individual companies have had a supercharged start to the year, dramatically outperforming the market benchmark.
Investors looking to capitalize on firms with rising momentum in 2026 might look to companies including Corvus Pharmaceuticals Inc. (NASDAQ: CRVS), New Era Energy & Digital Inc. (NASDAQ: NUAI), and USA Rare Earth (NASDAQ: USAR), all of which have returned at least 56% year-to-date (YTD).
Central banks are lying to you about gold (Ad)
Jerome Powell says gold is not money. The Fed says inflation is under control and the dollar is strong. But look at what they do. Central banks bought more gold last year than any time since 1967. China dumped $100 billion in U.S. debt, then bought gold. Poland, Hungary, Singapore, and Turkey are all loading up. In 2022, the U.S. froze Russia’s money and showed the world that assets can be seized. Now major nations want out. There’s only one asset no one can freeze: gold.Get the name and ticker of one stock positioned for this shift.
Analysts Stay Bullish on Corvus With 50%+ Upside Targets
As a clinical-stage biopharma company, Corvus is part of an industry that is often subject to rapid and sizable stock price swings in either direction. One of the latest catalysts for Corvus’ share price movement has been positive trial data from its drug candidate soquelitinib, used to treat atopic dermatitis, among other conditions. In mid-January, Corvus reported promising data from its Phase 1 trial, including a 72% reduction in the severity of eczema for patients in the trial.
This news has helped Corvus shares spike by an incredible 188% YTD. A Phase 2 trial is planned for early in the year and may help to drive shares up even further. In order to bankroll the upcoming trial, Corvus initiated a $150-million equity offering that should provide it with a much-needed cash runway, although this comes at the risk of diluting current shareholder positions. This is vital, however, because Corvus ended the third quarter of 2025 with only $67 million in cash reserves.
Although the company is perhaps banking on the continued success of soquelitinib, the potential addressable market of patients suffering from atopic dermatitis is sizable. Analysts view CRVS shares optimistically, with six out of seven labeling them a Buy and setting a consensus price target that suggests another 51% in growth could be in store, even after the latest rally.
New Era’s Data Center Pivot Makes Big Strides, Though Legal and Other Risks Remain
New Era & Digital is one of the more polarizing companies available to investors focused on the energy exploration and production industry in 2026. Shares of NUAI are up more than 114% YTD as the firm announced in January a key partnership with Primary Digital Infrastructure to deliver as much as a gigawatt of data center capacity to hyperscaler clients. The move is an essential step toward a new focus for the company as it attempts a pivot to the high-demand data center space. Earlier in the month, New Era also closed the acquisition of a 50% ownership interest in Texas Critical Data Centers, also helping to position it for a new focus.
All of this suggests that New Era could be successful in its ambitious reorganization plans. On the other hand, though, the company faces legal scrutiny as the Rosen Law Firm has announced plans to investigate allegations of “materially misleading business information.” New Era is also a small firm of just under $400 million in market value, so it carries a high level of risk for investors. Still, those willing to face these barriers may be rewarded should the rally continue.
The biggest scam in the history of gold markets is unwinding (Ad)
There are 90 paper gold claims for every real ounce in COMEX vaults. Ninety promises, one ounce of metal. It’s like musical chairs with 90 players and one chair. COMEX gold inventory dropped 25 percent last year alone as gold flows East to Shanghai, Mumbai, and Moscow. On March 31st, contract holders can demand delivery. When similar situations arose in the past, markets closed and rules changed. Paper holders got crushed while mining stock holders made fortunes. One stock sits at the center of this crisis.Get the full story on this opportunity now.
USA Rare Earth Looks to Fill a Significant Supply Chain Need With Government Support
Rare-earth minerals are increasingly vital in a range of technological applications, and supply chain and international trade concerns threaten to bottleneck U.S. supplies. USA Rare Earth aims to alleviate those concerns by providing a domestic alternative. The company has been buoyed by a $1.6-billion investment from the federal government and additional private investments in recent weeks, on top of a strong cash position reported alongside the latest earnings.
The firm’s rare-earth and magnet production capacity is growing rapidly, thanks to its key operations in Texas, and revenues are expected to grow massively. However, for the time being, USA Rare Earth is an early-stage firm without a proven track record of bottom-line performance, which may scare off some investors. That said, its 56% return this year and a strongly optimistic analyst rating profile suggest it could be destined for great things.
Read More
- Insiders Rang in the New Year Selling These Stocks, Buyers Beware
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company (From Banyan Hill Publishing)
- BlackRock Files for a Bitcoin Income ETF That Sells Options for Yield
- Trump’s boring AI play that could pay up to $4,290 monthly (From Investors Alley)
- 3 Stocks Trump Could Back Next as USA Rare Earths Revives the Federal Catalyst Trade
- Top 5 MarketRank™ Stocks Backed by Analysts and Big Institutions
- Defense Behemoths: Winners and Loser During Q4 Earnings Cycle
Did you find this article useful?
Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO’s, CFO’s, COO’s and other insiders.
If you have questions about your newsletter, feel free to contact MarketBeat’s U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
Copyright 2006-2026 MarketBeat Media, LLC. All rights protected.
345 North Reid Place #620, Sioux Falls, South Dakota 57103. United States of America..
Today’s Featured Link: Trump’s boring AI play that could pay up to $4,290 monthly (From Investors Alley)
Ask An Advisor: I’m 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (From Finance Advisors)
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
Written by Nathan Reiff on February 2, 2026
In Brief
- Corvus Pharmaceuticals has nearly tripled in value this year amid optimism that its atopic dermatitis drug candidate will continue to deliver strong trial results.
- Despite legal and other hurdles, New Era Energy & Digital recently noted a key achievement in its path toward providing data center capacity.
- USA Rare Earth has received around $1.6 billion in federal funding as it seeks to provide a domestic alternative to foreign rare earth minerals.
Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall after multiple dips throughout January. However, that middling performance might obscure the fact that a number of individual companies have had a supercharged start to the year, dramatically outperforming the market benchmark.
Investors looking to capitalize on firms with rising momentum in 2026 might look to companies including Corvus Pharmaceuticals Inc. (NASDAQ: CRVS), New Era Energy & Digital Inc. (NASDAQ: NUAI), and USA Rare Earth (NASDAQ: USAR), all of which have returned at least 56% year-to-date (YTD).
Central banks are lying to you about gold (Ad)
Jerome Powell says gold is not money. The Fed says inflation is under control and the dollar is strong. But look at what they do. Central banks bought more gold last year than any time since 1967. China dumped $100 billion in U.S. debt, then bought gold. Poland, Hungary, Singapore, and Turkey are all loading up. In 2022, the U.S. froze Russia’s money and showed the world that assets can be seized. Now major nations want out. There’s only one asset no one can freeze: gold.Get the name and ticker of one stock positioned for this shift.
Analysts Stay Bullish on Corvus With 50%+ Upside Targets
As a clinical-stage biopharma company, Corvus is part of an industry that is often subject to rapid and sizable stock price swings in either direction. One of the latest catalysts for Corvus’ share price movement has been positive trial data from its drug candidate soquelitinib, used to treat atopic dermatitis, among other conditions. In mid-January, Corvus reported promising data from its Phase 1 trial, including a 72% reduction in the severity of eczema for patients in the trial.
This news has helped Corvus shares spike by an incredible 188% YTD. A Phase 2 trial is planned for early in the year and may help to drive shares up even further. In order to bankroll the upcoming trial, Corvus initiated a $150-million equity offering that should provide it with a much-needed cash runway, although this comes at the risk of diluting current shareholder positions. This is vital, however, because Corvus ended the third quarter of 2025 with only $67 million in cash reserves.
Although the company is perhaps banking on the continued success of soquelitinib, the potential addressable market of patients suffering from atopic dermatitis is sizable. Analysts view CRVS shares optimistically, with six out of seven labeling them a Buy and setting a consensus price target that suggests another 51% in growth could be in store, even after the latest rally.
New Era’s Data Center Pivot Makes Big Strides, Though Legal and Other Risks Remain
New Era & Digital is one of the more polarizing companies available to investors focused on the energy exploration and production industry in 2026. Shares of NUAI are up more than 114% YTD as the firm announced in January a key partnership with Primary Digital Infrastructure to deliver as much as a gigawatt of data center capacity to hyperscaler clients. The move is an essential step toward a new focus for the company as it attempts a pivot to the high-demand data center space. Earlier in the month, New Era also closed the acquisition of a 50% ownership interest in Texas Critical Data Centers, also helping to position it for a new focus.
All of this suggests that New Era could be successful in its ambitious reorganization plans. On the other hand, though, the company faces legal scrutiny as the Rosen Law Firm has announced plans to investigate allegations of “materially misleading business information.” New Era is also a small firm of just under $400 million in market value, so it carries a high level of risk for investors. Still, those willing to face these barriers may be rewarded should the rally continue.
The biggest scam in the history of gold markets is unwinding (Ad)
There are 90 paper gold claims for every real ounce in COMEX vaults. Ninety promises, one ounce of metal. It’s like musical chairs with 90 players and one chair. COMEX gold inventory dropped 25 percent last year alone as gold flows East to Shanghai, Mumbai, and Moscow. On March 31st, contract holders can demand delivery. When similar situations arose in the past, markets closed and rules changed. Paper holders got crushed while mining stock holders made fortunes. One stock sits at the center of this crisis.Get the full story on this opportunity now.
USA Rare Earth Looks to Fill a Significant Supply Chain Need With Government Support
Rare-earth minerals are increasingly vital in a range of technological applications, and supply chain and international trade concerns threaten to bottleneck U.S. supplies. USA Rare Earth aims to alleviate those concerns by providing a domestic alternative. The company has been buoyed by a $1.6-billion investment from the federal government and additional private investments in recent weeks, on top of a strong cash position reported alongside the latest earnings.
The firm’s rare-earth and magnet production capacity is growing rapidly, thanks to its key operations in Texas, and revenues are expected to grow massively. However, for the time being, USA Rare Earth is an early-stage firm without a proven track record of bottom-line performance, which may scare off some investors. That said, its 56% return this year and a strongly optimistic analyst rating profile suggest it could be destined for great things.
Read More
- Insiders Rang in the New Year Selling These Stocks, Buyers Beware
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company (From Banyan Hill Publishing)
- BlackRock Files for a Bitcoin Income ETF That Sells Options for Yield
- Trump’s boring AI play that could pay up to $4,290 monthly (From Investors Alley)
- 3 Stocks Trump Could Back Next as USA Rare Earths Revives the Federal Catalyst Trade
- Top 5 MarketRank™ Stocks Backed by Analysts and Big Institutions
- Defense Behemoths: Winners and Loser During Q4 Earnings Cycle
Did you find this article useful?
Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO’s, CFO’s, COO’s and other insiders.
If you have questions about your newsletter, feel free to contact MarketBeat’s U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
Copyright 2006-2026 MarketBeat Media, LLC. All rights protected.
345 North Reid Place #620, Sioux Falls, South Dakota 57103. United States of America..
Today’s Featured Link: Trump’s boring AI play that could pay up to $4,290 monthly (From Investors Alley)
